In each region, data were evaluated from surveys that cited age specific OAG and ACG prevalences. For groups with insufficient population based prevalence data, estimates from hospital based data were used. The equation representing the best fit for existing estimates of glaucoma prevalence from individual surveys was used to generate a model of age specific and ethnic group specific prevalence estimates for the purposes of estimating global numbers of people with glaucoma.
Glaucoma is a common visual disorder whose frequency among people of the world has not been analysed comprehensively. Open angle glaucoma (OAG) is a slowly progressive atrophy of the optic nerve, characterised by loss of peripheral visual function and an excavated appearance of the optic disc by ophthalmoscopy. In each region, data were evaluated from surveys that cited age specific OAG and ACG prevalences. For groups with insufficient population based prevalence data, estimates from hospital based data were used. The equation representing the best fit for existing estimates of glaucoma prevalence from individual surveys was used to generate a model of age specific and ethnic group specific prevalence estimates for the purposes of estimating global numbers of people with glaucoma.
Results

EUROPEAN DERIVED PEOPLE
In the detailed analysis of studies among European derived people, the best fit of OAG prevalence5-23 related to age is an exponential Age (years) Figure 1 The 100 ACG and OAG are assumed to be equal. Despite reports that ACG may be more African, and Asian people common in women than in men, there are few survey data to support this conclusion; no sex difference is assumed. The practical consequence of this assumption is minimal, since in function: prevalence (%)=0-0059xe 0-08*age (adjusted r2=0 70) (Fig 1) . In this modelling, weights were assigned to data points to take account of the variance in prevalence, indicated by the number of cases and the total population. The mean age adjusted prevalence for adult European derived people (over age 40) was 2-42% (SD 2-10%). In this estimate, the data from surveys of people of European derivation5-23 were applied to the population data of those defined here as European derived. OAG here includes those with normal and elevated levels of IOP. The diagnosis required evidence that either functional visual loss or structural damage to the optic disc was present. The ratio of males to females suggested no consistent sex difference (mean male/female ratio=1 1 (SD 07) (n= 13).68 10 12 14-17 19 21-23 The age adjusted prevalence for ACG in nine studies5-7 10-12 19 21 23 averaged 0'20% (SD 0O20%) in those over 40 years. This is 11-4 times lower than the OAG prevalence in the same reports. Since the data were insufficient to estimate an age prevalence relation, it was assumed that ACG has the same exponential age relation as OAG, but 11 4 times lower. Males and females were presumed to be equally affected, as the stratification by sex produces groups too small for analysis.
AFRICAN DERIVED PEOPLE
The analysis of surveys2l [24] [25] [26] [27] [28] [29] of OAG among African derived people was provided previously. 4 The prevalence/age relation is linear: prevalence=0-27 (age)-0-22 (r2=0.52) (Fig  1) The comparison of glaucoma by age among regions reveals interesting differences. The total populations in the Africa and Europe groups are similar (723 million and 1 1 billion, respectively) and their OAG total numbers are similar (7 million and 6-9 million). However, owing to the earlier development of disease, the higher prevalence at younger ages, and differing demographic profiles, the distribution of disease by age is dramatically different in the two groups (Fig 2) . The burden of disease is substantially higher among younger people in the Africa group.
Discussion
There are few earlier estimates of the number with glaucoma among the various ethnic groups in the world.45 46 identify the earliest cases of glaucoma in order to have an impact. Given the relatively low disability/case ratio, the recognition of those at greatest risk of blindness would be a prudent approach. Initially at least, methods should be used that are sensitive enough to find those with moderate to severe glaucoma damage. This approach will have better specificity, decreasing the burden of examination of those improperly identified at screening. Furthermore, those already damaged may be more likely to agree to undergo therapy.
The therapy for glaucoma is less attractive to patients than cataract surgery, since vision can be retained, but not restored. Eyedrop treatment to lower IOP has been the initial therapy in developed countries, but its effectiveness and efficacy are being questioned. Daily medical treatment is expensive and subject to poor patient compliance. Initial surgery may be more effective at IOP lowering50 and is being compared with initial eyedrops in a US clinical trial. Antifibrotic agents as adjuncts to surgery5l 52 may produce acceptable rates of trabeculectomy success, especially if complications such as transient low IOP can be managed by releasable suture techniques.53 54 Coordination of glaucoma surgery with cataract surgery programmes would take advantage of economies of scale.
These prevalence estimates are based on a relatively small number of people detected in surveys, and are subject to the assumptions presented. Hopefully, others will generate additional data and improve the intuitive approach. Further studies of glaucoma prevalence are urgently needed in the groups of countries included here -China, India, South Asia, Latin America, and the Near East. Screening for ACG, which may represent half of worldwide glaucoma, is hampered by inadequate methods and lack of standardised diagnostic criteria.
Among the regions of the world, there are striking differences in the number of people affected by glaucoma owing to variation in age distributions. The appropriate age at which screening begins to be most effective in African people is 30 years, because of the earlier onset of disease and the high proportion of young people in this population. For the European derived, it seems most efficient to screen those over 50 years of age. Expected changes in world population will continue to increase the number and proportion of older people. The concomitant increases in those with cataract and glaucoma will expand the need for diagnostic and therapeutic services.
